The effect of hypnotherapy on the quality of life in women with breast cancer by Téllez, Arnoldo et al.
Psychology in Russia: State of the Art
Volume 10, Issue 2, 2017
Lomonosov
Moscow State
University
Russian
Psychological
Society
The effect of hypnotherapy on the quality  
of life in women with breast cancer
Arnoldo Téllez a, c *, Dehisy M. Juárez-García a, c, Leticia Jaime-Bernal c,  
Carlos E. Medina De la Garza b, c, Teresa Sánchez a 
a School of Psychology, Universidad Autónoma de Nuevo León, Nuevo León, Mexico
b School of Medicine, Universidad Autónoma de Nuevo León, Nuevo León, México
c Center for Research and Development in Health Sciences, Universidad Autónoma de Nuevo 
León, Nuevo León, México
* Corresponding author. E-mail: atellez50@hotmail.com
Background. Cancer is a chronic disease that significantly affects the quality of life of 
patients who suffer from it, because they must face stressful situations, including their 
diagnosis, surgical procedures, and the adverse effects of chemotherapy and radio-
therapy. 
objective. To evaluate the effects of hypnotherapy on breast cancer patients’ quality 
of life during chemotherapy.
design. A quasi-experimental design was used with a convenience sample. 
Method. Two groups of patients with early breast cancer diagnoses were assigned to 
either a control group that received standard medical care (n  =  20), or a hypnotherapy 
group (n  =  20) that received 12 intensive sessions over the course of 1 month, and 12 ad-
ditional sessions over the course of 6 months. The patients’ quality of life was evaluated 
using the European Organization for the Research and Treatment of Cancer Quality of 
Life Questionnaire Core 30 (EORTC QLQ-C30).
Results. The hypnotherapy group showed a statistically significant improvement 
and a large effect size on the cognitive functioning and social functioning scales com-
pared to the control group. The physical functioning, role functioning, and quality of life 
scales showed improvement with a medium effect size, but the changes were not statisti-
cally significant.
conclusion. The improvement observed in the cognitive functioning and social 
functioning scales allows us to suggest that hypnotherapy improves the quality of life of 
breast cancer patients during chemotherapy.
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introduction
According to the World Health Organization (WHO, 1948), health is a state of full 
physical, mental, and social well-being, not simply the absence of an illness or ail-
ment. By contrast, quality of life refers to general well-being, including physical, 
psychological, social, economic, and political features (Revicki et al., 2000). 
Health-Related Quality of Life (HRQOL) describes the quality of life of people 
who suffer from a specific illness, generally one that is chronic. Quality of life in 
these cases is affected by the debilitating consequences of the illness itself, or by the 
side effects of medical treatment. HRQOL can be defined as a subjective and multi-
dimensional state that encompasses physical, occupational, emotional, social, and 
cognitive functioning, as well as levels of vitality, pain, sexuality, and spirituality 
(Osoba, 2011). 
Cancer is a chronic disease that significantly affects the quality of life of patients 
who suffer from it because they must face stressful situations, including their diag-
nosis, surgical procedures, and the adverse effects of chemotherapy and radiother-
apy (Pocino et al., 2007). Women who have received medical treatment for breast 
cancer regularly report pain, fatigue, difficulty sleeping, nausea, vomiting, and hot 
flashes (Ewertz & Jensen, 2011).
Breast cancer patients’ quality of life varies according to the type of treatment. 
With regard to the type of surgery, radical surgery generates the greatest anxiety 
and self-image problems. By contrast, women who have had reconstructive and 
conservative surgery exhibit higher quality of life levels, particularly in dimensions 
such as physical functioning, emotional role, and social role (Roman, Olivares, 
Martín, Martin & Moreno, 2010; Royo, 2011).
Chemotherapy also negatively affects the quality of life of women who suffer 
from breast cancer, particularly because of the side effects that affect their physical, 
functional, and emotional state. Sat-Muñoz et al. (2011) found that the emotional 
dimension was the most strongly affected in Mexican women with breast cancer.
Longitudinal studies reveal that breast cancer patients’ quality of life is affected 
even 6, 9 or 12 months after the patients have finished treatment. The patients’ 
emotional functioning, role functioning and vitality are the dimensions that dete-
riorate the most, along with body image and sexual, cognitive, and social function-
ing (Domínguez et al., 2009; Härtl et al., 2010; Schou, Ekeberg, Sandvik, Hjermstad 
& Ruland, 2005). 
Because of the negative side effects that cancer treatment tends to have, a large 
portion of scientific studies have focused on finding therapeutic techniques and 
strategies to improve HRQOL in these patients (Fayers & Bottomley, 2002).
Hypnosis is a technique that has been used over the past few centuries to treat 
chronic diseases, and it has had positive results in providing physical and psycholog-
ical well-being for patients undergoing it (Montgomery, Schnur, & Kravits, 2013). 
Hypnosis has also been shown to be effective in managing various physical and psy-
chological symptoms in breast cancer patients, including distress, anxiety, hot flash-
es, fatigue, quality of sleep, and pain (Elkins, Fisher, Johnson, Carpenter, & Keith, 
2013; Jaime, Téllez, Juárez, García, & García, 2015; Montgomery et al., 2014). 
Moreover, hypnosis improves the quality of life in patients with metastases (Li-
ossi & White, 2001; Laidlaw, Bennet, Dwivedi, Nait & Gruzelier, 2005). A review by 
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Cramer et al. (2014) confirms these findings. However, to our knowledge, the direct 
effects of hypnotherapy on quality of life and the elements of functioning during 
chemotherapy, have not been studied previously. 
The purpose of this study was to determine the effects of hypnotherapy on the 
quality of life of women with breast cancer during chemotherapy, compared to a 
control group that received standard medical care. 
Method
This paper is a secondary analysis of a broader study of the effects of hypnosis on 
the well-being of breast cancer patients, in which components of the quality-of-life 
variable are analyzed. The psychosocial variables studied by this team are available 
in another publication (Téllez et al, 2017). A quasi-experimental design was used 
with a convenience sample. 
Participants
Fifty-six patients were invited to participate. Of these, 16 rejected the invitation. 
Thus 40 women with breast cancer were included in the initial stages (I, II, and III). 
These women had no metastases, no prior cancers, no previous participation in 
hypnotherapy, and were scheduled to receive chemotherapy within the following 2 
weeks. In the second phase of the study, 4 patients left the study voluntarily: 2 from 
the intervention group and 2 from the control group.
In terms of socio-demographic characteristics, the median age was 52 years 
for the intervention group and 52.2 years for the control group. With regard to 
the marital status of the hypnotherapy group, 10 % were single, 45 % were mar-
ried, 15 % were in a domestic partnership, 15 % were separated, and 15 % were 
widowed. In the control group, 15 % were single, 65 % were married, 5 % were in 
a domestic partnership, 10 % were separated, and 5 % were widowed. All those 
in the hypnotherapy group and 85 % of those in the control group had children. 
With regard to socioeconomic status, the intervention group was 55 % lower-
class and 45 % middle-class, whereas the control group was 25 % lower-class and 
75 % middle-class.
Procedure
This study was performed in Mexico, and was approved by the ethics committee in 
Health Science of Universidad Autónoma de Nuevo León. All of the participants 
signed an informed consent form prior to beginning the procedure. 
The 40 patients were referred by an oncologist who was part of the research 
group. The first 20 patients referred were assigned to the hypnotherapy interven-
tion group, and the next 20 patients were assigned to the control group with stan-
dard medical care only. 
The intervention consisted of 24 hypnotherapy sessions, each lasted 90 min-
utes, and was divided into 2 phases. The first phase involved 12 intensive sessions, 
with a frequency of 3 sessions per week, over the course of 1 month. The second 
phase involved 12 sessions, with a frequency of 1 session fortnightly, for 6 months. 
These sessions occurred throughout the chemotherapy treatment.
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Evaluations were conducted before treatment, and at the end of the first and 
second phase. Evaluations of the control group were conducted in tandem with the 
evaluations of the intervention group. 
Hypnotherapeutic intervention
hypnotic intervention: In each session, a suggestive technique was used targeting 
specific symptoms for an average of 20 minutes. After the first hypnotic induction, 
a 10-minute pause was taken to discuss the experience, and have the patients rated 
their feeling of relaxation on a visual analogue scale from 1 to10.
second hypnotic technique: The Battino and South (2005) technique was used 
in the 24 sessions, This technique consists of taking the patient’s hand and giving 
her a series of suggestions directed at strengthening the immune system.
Each of the patients in the hypnotherapy group received MP3 equipment to 
listen to the hypnotherapy techniques at home.
In Phase 1, two sessions focused on physical and psychological relaxation (Field, 
1990), and one session focused on facilitating sleep and relaxation (Téllez, 2007). 
Three sessions focused on strengthening self-esteem (Pelletier, 1979; Torem, 1990; 
Cobián, 1997), four sessions focused on resolving traumatic events from the past 
(Watkins & Watkins, 1990; Watkins, 1980; Wright, 1987; Greenberg & Malcolm, 
2002), one session focused on physical healing (Dilts, Smith, Halbom &, 1998), and 
one session was directed at increasing optimism (Korn & Pratt, 1990).
In Phase 2, five sessions were focused on physical healing (Hammond, 1990), 
two on physical and psychological relaxation (Hammond, 1990; Sacerdote, 1977), 
two sessions focused on strengthening self-esteem (Gorman, 1974; Pekala & Ku-
mar, 1999), two sessions were used to strengthen positive expectations and motiva-
tion for change (Hammond, 1990; Téllez, 2007), and another session was used to 
facilitate sleep and relaxation (Stanton, 1990).
Measures
The quality of life evaluation was performed using the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-
C30), which is an integrated system used to evaluate the quality of life of patients 
with cancer diagnoses. The EORTC QLQ-C30 consists of 30 items, 24 of which are 
organized into 9 multi-item scales that represent various dimensions of quality of 
life: an overall scale; 5 functioning scales (physical, role, emotional, cognitive, and 
social); and 3 scales to measure symptoms (fatigue, pain, and nausea) (Aaronson 
et al., 1993). The EORTC QLQ-C30 is considered to be highly sensitive in detect-
ing changes in well-being in cancer patients during chemotherapy (Uwer et al., 
2011). 
Data analysis
The data were analyzed using SPSS Statistics V. 21.0. A one-way analysis of variance 
(ANOVA) with a change score was used, as recommended by Huck and McLean 
(1975), to adjust any possible differences in the pre-test evaluation. Additionally, 
the size effect was obtained using the formula for pretest/post-test designs with a 
232  A. Téllez, D. M. Juárez-García, L. Jaime-Bernal, C. E. Medina De la Garza, T. Sánchez
control group, using the adjustment to reduce bias (Morris, 2008). The confidence 
intervals for effect size were obtained using the Campbell collaboration online cal-
culator (Lipsey & Wilson, 2001).
The clinical significance, or practical value, of hypnotherapy was judged by 
evaluating the size of its effect according to the Cocks et al. (2011) guide. These 
authors established guidelines for evaluating differences between QLQ-C30 scores. 
The authors used 4 effect size categories: large (l) = unequivocal clinical relevance; 
medium (m) = clinical relevance is probable, but to a lesser degree; small (s) = a 
change that is subtle but clinically relevant; and trivial = situations that are unli-
kely to have clinical relevance, or in which there were no differences. Likewise, the 
 authors note that these effects sizes are different in each functioning scale: cogni-
tive 3–9 (s), 11–15 (m), and >15 (l); physical 5–14 (s), 14–22 (m), and >22 (l); role 
6–19 (s), 19–29 (m), and >29 (l); social 5–11 (s), 11–15 (m), and >15 (l); and overall 
quality of life 4–10 (s), 10–15 (m), and >15 (l). 
Results
By group
In the first month of intensive treatment, significant differences were observed in 
the hypnotherapy group, with regard to the scales for physical and social function-
ing and overall quality of life. The last 2 scales showed a large effect size.
After 6 months, the most notable changes were observed on the scales for cog-
nitive functioning (p = 0.011, d = 1.18) and the social functioning scale (p = 0.015; 
d = 1.02), with a large effect size.
Regarding physical functioning, a large effect size was observed (d = 0.91), 
whereas for role functioning (d = 0.58) and overall quality of life (d = 0.51), a me-
dium effect size was observed, but this was not statistically significant (Table 1). 
Therefore, if there is a therapeutic effect, its statistical significance would have to be 
achieved by increasing the sample size (statistical power) (Téllez, García & Corral, 
2015).
On the symptom scales, although the patients in the intervention group showed 
a greater reduction in symptoms, the changes were not significant (Table 2).
Analysis using the Cocks et al. (2011) guide
According to the Cocks et al. (2011) interpretation guide, the scores obtained by 
the hypnotherapy group revealed an improvement with a small effect size in regard 
to social functioning at the end of the first month, and at the end of 6 months (8.5 
and 10 points, respectively). An improvement was obtained in regard to overall 
quality of life, with a medium effect size at the end of 1 month (13 points), and a 
small effect size at the end of 6 months (6 points). Hypnotherapy had a trivial effect 
on cognitive functioning during the first month; however, there was an improve-
ment with a large effect at the end of 6 months (19 points) (Figure 1).
The control group scores illustrated deterioration in various scales. Cognitive 
functioning exhibited deterioration with a small effect size after 1 month and after 
6 months (–3 and –6 points, respectively). Social functioning also exhibited dete-
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figure 1. Mean score change in cognitive functioning (QLQ-C30) mea-
sured at baseline and after 1 and 6 months in hypnotherapy and control 
conditions. This figure shows an improvement in cognitive functioning 
in the hypnosis group and a decline in the control group.
rioration, with a small effect size after 1 month (–11) and a large effect size after 6 
months (–19). Overall quality of life deteriorated with a small effect size after the 
first month and after 6 months (–5.8 and –5.3, respectively).
Analysis by the number of patients with clinical changes
The results obtained here were similar to the analyses of the group scores. Af-
ter 6 months, the patients in the control group worsened nearly 8 times more (6 
vs 47 %) (p = 0.003, d = 1.04) in terms of cognitive functioning, and 3 times more 
in terms of social functioning and overall quality of life, than those undergoing 
hypnotherapy. All of these factors had a large effect size and were statistically sig-
nificant. The control group also had a higher number of patients whose physical 
and role functioning worsened, with a medium effect size that was not statisti-
cally significant. No changes were observed with regard to emotional functioning 
(Table 3).
table 3. Proportion of patients whose scores worsened on the QLQ-C30 scales (decline in 
the effect size of d < 0.50).
QlQ-c30  
functioning scale 
 % Px Worsened 
hypnosis
 % Px Worsened 
control
p-value effect size 
(cohen´s d)
Physical 22 59 0.11 0.66*
Role 28 47 0.12 0.54*
Emotional 16 11 0.38 0.43
Cognitive 6 47 0.003 1.04**
Social 17 59 0.03 0.80**
Global QoL 11 41 0.05 0.80**
* Medium effect size ** Large effect size. Px: patient
 control   hypnosis
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discussion
This study shows that 24 group hypnotherapy sessions over a period of 6 months 
improved the quality of life for women with breast cancer during chemotherapy 
treatment. In the three analyses performed, the functioning scales that showed im-
provement occurred for social, physical, and cognitive functioning, and for overall 
quality of life based on the QLQ-C30, with medium to large effect sizes. The scales 
for emotional functioning, role, and symptoms did not reveal significant differ-
ences.
The use of different types of analysis, such as Fisher’s exact test to measure the 
number of patients who improve or worsen, as well as the interpreting of QLQ-
C30 scores using the Cocks et al. (2011) guide, allowed us to determine whether 
the treatment, in this case hypnotherapy, makes a real or palpable difference in the 
patient’s daily life (Kazdin, 1999). 
One of the most notable effects of hypnotherapy was the improvement in cog-
nitive functioning. Cognitive alterations are among the most common symptoms 
related to cancer (Janelsins et al., 2011). Evaluations of overall cognitive function-
ing as well as immediate free recall, delayed memory, verbal memory, selective at-
tention, attention span, and abstract reasoning indicate deterioration during and 
after breast cancer-treatment-related procedures (Lindner et al., 2014; Biglia et al., 
2012; Vearncombe et al., 2009; Ando-Tanabe et al., 2014).
Härtl et al., (2010) found out that after a mastectomy and with the passage of 
time, all QLQ-C30 functioning scales improve, except cognitive functioning. In-
deed, these cognitive deficits can be detected up to 20 years after having finished 
chemotherapy (Koppelmans et al., 2012). 
Although evidence exists of cognitive alterations produced by medical treat-
ment in patients with breast cancer, few studies have demonstrated the effective-
ness of psychological techniques in improving or preventing cognitive decline in 
these patients. Some of the strategies that have demonstrated effectiveness in im-
proving cognitive alterations related to chemotherapy include cognitive training 
(King & Green, 2015) and neuropsychological rehabilitation (Poppelreuter, Weis, 
& Bartsch, 2009). However, our study provides the first evidence that hypnotherapy 
has a positive effect on self-reported cognitive functioning, which suggests that 
hypnotherapy can be a useful tool in avoiding cognitive decline in patients with 
cancer. However, it would be advisable to use specific neuropsychological tests to 
confirm this finding.
Furthermore, although some studies have found that social functioning is not 
affected during chemotherapy (Recalde & Samudio, 2012; Denieffe, Cowman, & 
Gooney, 2013), in this study, the control group declined by 20 points on this scale, 
whereas the hypnotherapy group improved by 10 points. In other words, there was 
a difference of almost 30 points between the 2 groups. Richardson et al. (1997) 
also reported an improvement in this type of functioning using guided imagery. 
Efficace et al. (2006) highlight the importance of social functioning because it is a 
predictive factor in cancer patient survival.
Likewise, in the hypnotherapy group, trivial changes were observed in physical 
functioning after the first month, and no changes were observed after 6 months, 
whereas the control group worsened in this aspect. This indicates that hypnother-
apy patients maintained their normal level of physical functioning in spite of the 
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chemotherapy treatment, and, as Kazdin (1999) has noted, a small change, and 
even a lack of change, can be clinically relevant.
Physical functioning is important because it allows patients to achieve a certain 
level of independence in performing their day-to-day activities, including getting 
out of bed, dressing, and eating. It also increases the likelihood that the patient 
will be able to reintegrate into work and social life, and improve her quality of life 
(Campbell et al., 2012). 
Compared to the control group, the overall quality of life of patients in the 
intervention group improved. This is important because the perception of overall 
quality of life implies a sense of general well-being for patients in their daily lives 
(Bellver, 2007). Overall quality of life is one of the main factors taken into consid-
eration in developing and implementing effective interventions to promote well-
being and reduce the individual and social effects of cancer (Weaver et al., 2012). 
As such, hypnotherapy can be considered an intervention that promotes quality of 
life and the perception of well-being in patients with breast cancer.
In regard the role and emotional functioning scales, in the former we observed 
small changes, although they were not significant, whereas no changes were ob-
served in terms of emotional functioning. One possible explanation for this result 
could be that this scale was considered informative by the patients reporting, and 
was not very sensitive to clinical changes (Cocks et al., 2011).
conclusion
This study described the benefits of hypnotherapy for the quality of life of women 
with cancer who receive chemotherapy. However, it ought to be mentioned that the 
convenience sampling, the small sample size, and the lack of follow-up limit the 
generalizability of the results. For this reason, we suggest that a randomized clini-
cal trial be performed with follow-up and sufficient statistical power to confirm 
these results. Additionally, it is important to use specific instruments to evaluate 
the different scales. For example, it is necessary to use neuropsychological tests to 
measure cognitive functioning, rather than rely on self-reporting.
This study offers preliminary evidence of the utility of hypnotherapy during 
chemotherapy in increasing cognitive functioning and reducing adverse effects on 
social and physical functioning and overall quality of life in women with breast 
cancer. 
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